Reaction
Breast Cancer Stage Iv reporting signals
As of the last recalculation, Breast Cancer Stage Iv appears in 2,835 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is RANITIDINE HYDROCHLORIDE (PRR 13.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranitidine Hydrochloride | 97 | 13.5 | 13.6 |
| Fulvestrant | 50 | 11.3 | 11.3 |
| Ribociclib | 41 | 9.7 | 9.7 |
| Letrozole | 79 | 9.7 | 9.7 |
| Alpelisib | 10 | 8.4 | 8.5 |
| Letrozole Tablets | 52 | 8.1 | 8.1 |
| Ranitidine | 185 | 7.2 | 7.2 |
| Anastrozole Tablets | 19 | 6.5 | 6.5 |
| Anastrozole | 31 | 6.3 | 6.3 |
| Exemestane | 16 | 5.5 | 5.5 |
| Palbociclib | 68 | 5.3 | 5.3 |
| Goserelin | 9 | 4.9 | 4.9 |
| Everolimus | 25 | 3.6 | 3.6 |
| Ado-Trastuzumab Emtansine | 4 | 3.5 | 3.5 |
| Lapatinib | 7 | 3.3 | 3.3 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 2.2 | 2.2 |